(19)
(11) EP 2 997 035 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
23.05.2018 Bulletin 2018/21

(45) Mention of the grant of the patent:
28.03.2018 Bulletin 2018/13

(21) Application number: 14723820.8

(22) Date of filing: 14.05.2014
(51) International Patent Classification (IPC): 
C07J 9/00(2006.01)
A61K 31/575(2006.01)
C07J 71/00(2006.01)
 C07J 41/00(2006.01)
A61P 1/16(2006.01)
C07J 31/00(2006.01)
(86) International application number:
PCT/EP2014/059896
(87) International publication number:
WO 2014/184271 (20.11.2014 Gazette 2014/47)

(54)

11-HYDROXYL-6-SUBSTITUTED-DERIVATIVES OF BILE ACIDS AND AMINO ACID CONJUGATES THEREOF AS FARNESOID X RECEPTOR MODULATORS

11-HYDROXYL-6-SUBSTITUIERTE-DERIVATIVE VON GALLENSÄUREN UND AMINOSÄUREKONJUGATE DAVON ALS FARNESOID-X-REZEPTORMODULATOREN

DÉRIVÉS 11-HYDROXYLE D'ACIDES BILIAIRES SUBSTITUÉS EN POSITION 6 ET LEURS CONJUGUÉS D'ACIDES AMINÉS EN TANT QUE MODULATEURS DU RÉCEPTEUR DE FARNÉSOÏDE X

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: 14.05.2013 US 201361823169 P

(43) Date of publication of application:
23.03.2016 Bulletin 2016/12

(60) Divisional application:
18163622.6
18163623.4

(73) Proprietor: Intercept Pharmaceuticals, Inc.
New York, NY 10001 (US)

(72) Inventor:
  • PELLICCIARI, Roberto
    I-06129 Perugia (IT)

(74) Representative: Cooley (UK) LLP 
Dashwood 69 Old Broad Street
London EC2M 1QS
London EC2M 1QS (GB)


(56) References cited: : 
EP-A1- 0 124 903
WO-A2-2004/007521
 EP-A1- 1 568 706
US-A- 2 802 775
   
  • HITOSHI ISHIDA ET AL: "Study on the Bile Salts from Sunfish, Mola mola L. I. The Structures of Sodium Cyprinol Sulfates, the Sodium Salt of a New Bile Acid Conjugated with Taurine, and a New Bile Alcohol and Its New Sodium Sulfates.", CHEMICAL & PHARMACEUTICAL BULLETIN, vol. 46, no. 1, 1 January 1998 (1998-01-01), pages 12-16, XP55128539, ISSN: 0009-2363, DOI: 10.1248/cpb.46.12
  • WILLIAM P LONG ET AL: "PARTIAL SYNTHESIS OF COMPOUNDS RELATED TO ADRENAL CORTICAL HORMONES: III. PREPARATION OF 3([alpha]), 11([alpha])-DIHYDROXYCHOLANIC ACID", J. BIOL. CHEM., vol. 162, no. 3, 1 March 1946 (1946-03-01) , pages 511-519, XP55128534,
  • PELLICCIARI R ET AL: "Bile Acid Derivatives as Ligands of the Farnesoid X Receptor. Synthesis, Evaluation, and Structure-Activity Relationship of a Series of Body and Side Chain Modified Analogues of Chenodeoxycholic Acid", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 47, 23 July 2004 (2004-07-23), pages 4559-4569, XP002370634, ISSN: 0022-2623, DOI: 10.1021/JM049904B
  • SIMONA DE MARINO ET AL: "Theonellasterols and Conicasterols from Theonella swinhoei . Novel Marine Natural Ligands for Human Nuclear Receptors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 54, no. 8, 28 April 2011 (2011-04-28) , pages 3065-3075, XP55128555, ISSN: 0022-2623, DOI: 10.1021/jm200169t
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).